Core Insights - The company reported a third-quarter revenue of 361 million yuan, representing a year-on-year increase of 11.08% [1] - The net profit for the third quarter was 45.73 million yuan, showing a significant year-on-year growth of 58.78% [1] - For the first three quarters, the total revenue reached 1.092 billion yuan, which is a year-on-year increase of 4.51% [1] - The net profit for the first three quarters amounted to 176 million yuan, reflecting a year-on-year growth of 7.39% [1]

Financial Performance - The company's revenue for Q3 2025 reached ¥360,864,815.60, representing an increase of 11.08% compared to the same period last year[5] - Net profit attributable to shareholders was ¥45,728,260.43, a significant increase of 58.78% year-on-year[5] - The basic earnings per share for the period was ¥0.0551, reflecting a growth of 55.65% compared to the previous year[5] - Total operating revenue for the current period reached ¥1,092,285,389.95, an increase of 4.5% compared to ¥1,045,172,312.93 in the previous period[18] - Net profit for the current period was ¥209,552,451.74, representing a 10% increase from ¥190,509,038.34 in the previous period[19] - Earnings per share (EPS) for the current period was ¥0.2148, compared to ¥0.2017 in the previous period, indicating a growth of 15.4%[20] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥3,487,847,864.98, marking a 5.64% increase from the end of the previous year[5] - The company’s financial assets increased by 339.90% to ¥462,589,373.70 due to increased investment in financial products[8] - Total current assets increased from 1,844,302,643.64 CNY to 1,954,574,731.10 CNY, an increase of about 6%[15] - The total liabilities increased to ¥393,504,467.73 from ¥344,656,275.77, representing a growth of 14.2%[17] - Total equity rose to ¥3,094,343,397.25 from ¥2,957,123,501.37, indicating an increase of 4.6%[17] Cash Flow - The company reported a net cash flow from operating activities of ¥224,559,700.16, which is a 22.81% increase year-to-date[5] - Cash inflow from operating activities totaled ¥1,125,494,646.11, an increase from ¥1,054,807,090.96 in the previous period, marking a growth of 6.7%[21] - The net cash flow from operating activities was $224,559,700.16, an increase of 23% compared to $182,850,167.68 in the previous period[22] - Cash inflow from investment activities totaled $891,894,302.17, up from $710,856,913.71, marking a 25.5% increase[22] - The net cash flow from investment activities was -$476,496,188.50, a significant decrease from $303,073,347.40 in the prior period[22] Shareholder Information - Total number of common shareholders at the end of the reporting period is 88,812[11] - The largest shareholder, Nantong Industrial Holdings Group Co., Ltd., holds 33.75% of shares, totaling 279,994,660 shares[11] - The company has no preferred shareholders as indicated in the report[13] Expenses - Total operating costs amounted to ¥853,284,673.64, up from ¥825,883,624.70, reflecting a year-over-year increase of 3.3%[18] - Research and development expenses were ¥43,536,583.86, slightly down from ¥47,149,976.95, showing a decrease of 7%[19] - Sales expenses increased to ¥203,123,914.20 from ¥183,281,978.47, reflecting an increase of 10.8%[19] Investment Activities - The company’s investment payments surged by 224.66% to ¥1,233,700,000.00, reflecting a significant increase in financial product purchases[9] - The company’s cash flow from other investment activities decreased by 77% to ¥10,618,402.78, primarily due to reduced cash recovery from related activities[9] - The company received $878,000,000.00 from the recovery of investments, an increase from $656,137,829.10[22] - The company paid $121,051,082.31 in cash related to other investment activities, significantly higher than $1,117,714.05 in the previous period[22]

Market Overview - The Chinese traditional medicine sector experienced a decline of 0.31% on October 27, with Zhenbaodao leading the drop [1] - The Shanghai Composite Index closed at 3996.94, up 1.18%, while the Shenzhen Component Index closed at 13489.4, up 1.51% [1] Stock Performance - Notable gainers in the traditional medicine sector included: - Weikang Pharmaceutical (300878) with a closing price of 23.90, up 3.46% [1] - ST Xiangxue (300147) at 10.25, up 2.60% [1] - Jiuzi Tang (000989) at 10.02, up 2.14% [1] - Conversely, Zhenbaodao (603567) saw a significant decline of 6.23%, closing at 11.13 [2] - Other notable decliners included: - Taiji Group (600129) down 3.21% [2] - Kunming Pharmaceutical Group (600422) down 2.21% [2] Capital Flow - The traditional medicine sector experienced a net outflow of 344 million yuan from institutional investors, while retail investors saw a net inflow of 181 million yuan [2] - The sector's overall capital flow indicated a mixed sentiment, with speculative funds showing a net inflow of 163 million yuan [2] Individual Stock Capital Flow - Key stocks with significant capital flow included: - Jilin Aodong (000623) with a net inflow of 81.97 million yuan from institutional investors [3] - Yunnan Baiyao (000538) with a net inflow of 62.26 million yuan [3] - Jiuzi Tang (000989) with a net inflow of 26.22 million yuan [3] - Notable outflows were observed in: - Jilin Aodong with a retail net outflow of 72.25 million yuan [3] - Yunnan Baiyao with a retail net outflow of 67.54 million yuan [3]

Core Viewpoint - The company, Jinghua Pharmaceutical, indicated on October 20 that it will adjust its production pace according to market conditions to ensure market supply [2] Company Summary - Jinghua Pharmaceutical is actively monitoring market conditions to make timely adjustments in its production schedule [2]

Core Insights - On October 16, Jinghua Pharmaceutical's stock price remained unchanged at 0.00%, with a trading volume of 70.49 million yuan [1] - The company experienced a net financing outflow of 5.15 million yuan on the same day, with a total financing balance of 163 million yuan, representing 2.74% of its market capitalization [1] - As of June 30, 2025, Jinghua Pharmaceutical reported a revenue of 731 million yuan, a year-on-year increase of 1.54%, while its net profit attributable to shareholders decreased by 3.54% to 131 million yuan [2] Financing and Margin Trading - On October 16, the financing buy amount for Jinghua Pharmaceutical was 3.10 million yuan, with a total financing balance of 163 million yuan, which is below the 40th percentile of the past year [1] - The company had a margin trading balance of 67,400 yuan, with a short selling volume of 0 shares on October 16, indicating low activity in this area [1] Shareholder Structure - As of June 30, 2025, the number of shareholders for Jinghua Pharmaceutical was 95,900, a decrease of 5.29% from the previous period, while the average number of circulating shares per person increased by 5.58% to 8,492 shares [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 4.48 million shares to 8.53 million shares, while the Huatai-PineBridge CSI Traditional Chinese Medicine ETF reduced its holdings by 243,700 shares to 2.68 million shares [3]

证券代码：002349 证券简称：精华制药 公告编号：2025-042 精华制药集团股份有限公司 2025年第二次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、会议召开和出席情况 精华制药集团股份有限公司（以下简称"公司"）2025年第二次临时股东会 采取现场投票与网络投票相结合方式进行，现场会议于2025年10月14日下午 14:30在公司会议室召开，会议由公司董事会召集，由董事长尹红宇先生主持。 公司董事、董事候选人、高级管理人员出席了会议。通过深圳证券交易所交易系 统进行网络投票的时间为2025年10月14日上午9:15-9:25，9:30-11:30 和下午 13:00～15:00；通过深圳证券交易所互联网投票系统投票的时间为2025年10月14 日上午9:15至下午15:00期间的任意时间。 特别提示： 本 次 会 议 的 通 知 已 于 2025 年 9 月 19 日 在 《 巨 潮 资 讯 网 》 （http://www.cninfo.com.cn）、《中国证券报》上发出，本次会议召开期间无 增加、否决或变更提案的情况， ...

北京市盈科(南通)律师事务所 关于精华制药集团股份有限公司 2025年第二次临时股东会的法律意见书 致：精华制药集团股份有限公司 受贵公司的委托，北京市盈科(南通)律师事务所（以下简称"本 所"）根据《中华人民共和国公司法》（以下简称"《公司法》"）、 《上市公司股东会规则》(以下简称"《股东会规则》")等法律、法 规、规章及《精华制药集团股份有限公司章程》（以下简称"《公司 章程》"）的有关规定，就公司2025年第二次临时股东会（以下简称 "本次股东会"）有关事宜，出具本法律意见。本法律意见书仅就本 次股东会的召集和召开程序、出席本次股东会人员的资格、召集人资 格、会议表决程序是否符合中国相关法律、法规及《公司章程》的规 定以及表决结果是否合法有效发表意见，并不对本次股东会所审议的 议案内容以及该等议案所表述的相关事实或数据的真实性、准确性或 合法性发表意见。 本所及本所律师依据《证券法》《律师事务所从事证券法律业务 管理办法》和《律师事务所证券法律业务执业规则（试行）》等规定 及本法律意见书出具日以前已经发生或者存在的事实，严格履行了法 定职责，遵循了勤勉尽责和诚实信用原则，进行了充分的核查验证， 保证本 ...

Core Viewpoint - The company Jinghua Pharmaceutical (002349.SZ) does not currently produce any drugs specifically for the treatment of respiratory syncytial virus (RSV) [1] Product Overview - The company's product Qingzhai Hu Yin Granules is used for symptoms such as fever, chills, headache, nasal congestion, sneezing, throat itching, cough, and limb soreness, suitable for initial stages of influenza and mild upper respiratory infections [1] - The product Wang's Baochi Pill is effective for pediatric conditions like milk stagnation, phlegm-induced seizures, cough with phlegm, reduced milk intake, diarrhea with fever, seasonal colds, as well as for adults with gastrointestinal issues [1] - The product Jin Qiao Mai Pian has functions of clearing heat and detoxifying, promoting pus discharge, and relieving cough and asthma, mainly used for acute lung abscess, acute and chronic bronchitis, asthma, and bacterial dysentery [1] - The product Ji Desheng Snake Medicine Tablets has effects of clearing heat and detoxifying, reducing swelling and relieving pain, treating snake and insect bites, and has unique efficacy against viral infections, bacterial infections, and immune deficiencies [1]

Core Viewpoint - The company announced the election of Mr. Qin Jian as the employee director of the sixth board of directors during the first employee representative assembly of the fifth session, held on October 13, 2025 [2] Summary by Relevant Sections - **Company Announcement** - The company held its first employee representative assembly of the fifth session on October 13, 2025 [2] - Mr. Qin Jian was elected as the employee director for the sixth board of directors [2]

Core Viewpoint - The company emphasizes the importance of market value management and aims to enhance operational efficiency to promote market value growth [1] Group 1 - The company is committed to improving its internal value to drive market value enhancement [1] - Stock price movements are influenced by various factors including macroeconomic conditions, industry fluctuations, and market sentiment [1]